StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD - Free Report) from a hold rating to a buy rating in a research report report published on Saturday.
A number of other analysts have also recently weighed in on FOLD. Guggenheim upped their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald increased their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Morgan Stanley reduced their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.63.
Check Out Our Latest Stock Report on FOLD
Amicus Therapeutics Price Performance
NASDAQ FOLD traded down $0.41 during trading on Friday, reaching $9.68. 2,649,983 shares of the company traded hands, compared to its average volume of 2,727,982. Amicus Therapeutics has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a market cap of $2.89 billion, a price-to-earnings ratio of -28.47 and a beta of 0.68. The stock's 50 day moving average price is $11.00 and its two-hundred day moving average price is $10.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.
Insider Transactions at Amicus Therapeutics
In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $9,398,532.40. The trade was a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 30,401 shares of company stock worth $352,038. Corporate insiders own 2.20% of the company's stock.
Institutional Investors Weigh In On Amicus Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP boosted its holdings in Amicus Therapeutics by 13.5% during the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock worth $255,936,000 after buying an additional 2,856,101 shares during the last quarter. Janus Henderson Group PLC increased its stake in Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company's stock valued at $162,713,000 after purchasing an additional 2,307,385 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in Amicus Therapeutics by 583.4% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company's stock worth $25,640,000 after purchasing an additional 1,858,100 shares during the period. Millennium Management LLC boosted its position in shares of Amicus Therapeutics by 1,758.9% during the second quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company's stock worth $18,790,000 after purchasing an additional 1,792,277 shares in the last quarter. Finally, William Blair Investment Management LLC grew its holdings in shares of Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company's stock valued at $128,993,000 after buying an additional 1,477,084 shares during the period.
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Stories
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
